Your browser doesn't support javascript.
loading
Considerations for development of therapies for cutaneous neurofibroma.
Verma, Sharad K; Riccardi, Vincent M; Plotkin, Scott R; Weinberg, Hubert; Anderson, R Rox; Blakeley, Jaishri O; Jarnagin, Kurt; Lee, James.
Afiliación
  • Verma SK; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Riccardi VM; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Plotkin SR; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Weinberg H; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Anderson RR; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Blakeley JO; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Jarnagin K; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
  • Lee J; From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital,
Neurology ; 91(2 Suppl 1): S21-S30, 2018 07 10.
Article en En | MEDLINE | ID: mdl-29987132
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neurofibromatosis 1 / Desarrollo de Medicamentos / Neurofibroma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Neurology Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neurofibromatosis 1 / Desarrollo de Medicamentos / Neurofibroma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Neurology Año: 2018 Tipo del documento: Article